FIELD: anti-ischemic agents.
SUBSTANCE: invention relates to the use of salicyl-beta-alanyl-L-histidine (salicyl-carnosine) as a neuroprotective anti-ischemic agent in the form of the viability of neurons in a primary culture of rat cerebral cortex cells under conditions of glucose-oxygen deprivation and in a model of NMDA-induced excitotoxicity.
EFFECT: invention provides the ability to use salicyl-beta-alanyl-L-histidine (salicyl-carnosine) as a neuroprotective anti-ischemic agent.
1 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REMEDY WITH ANTIOXIDANT AND NEUROPROTECTIVE ACTIVITY | 2021 |
|
RU2777391C1 |
| AGENT POSSESSING ANTIAGGREGANT, CYTOPROTECTIVE AND ANTIOXIDANT ACTIVITY | 2018 |
|
RU2694061C1 |
| METHOD FOR EVALUATING THE BIOLOGICAL ACTIVITY OF A TETRADECAPEPTIDE | 2017 |
|
RU2667120C1 |
| METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS | 2014 |
|
RU2687097C2 |
| 3R,4S 3-[4-(4-FLUOROPHENYL)-4-HYDROXYPIPERIDIN-1- YL)CHROHAN-4,7-DIOL, OPTICAL ISOMERS THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON, AND METHOD OF MEDICAL TREATMENT | 1994 |
|
RU2126404C1 |
| METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
| CARDIOTROFIN APPLICATION IN LIVER DISEASES | 2002 |
|
RU2279289C2 |
| METHOD FOR PREVENTING AND CORRECTING METABOLIC AND FUNCTIONAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM UNDER STRESS CONDITIONS | 2019 |
|
RU2717107C1 |
| NEUROPROTECTIVE AGENT | 2016 |
|
RU2614697C1 |
| THERAPEUTIC COMPOSITION FOR REDUCING RESISTANCE TO TYROSINE KINASE INHIBITORS | 2016 |
|
RU2735493C2 |
Authors
Dates
2022-09-19—Published
2022-02-18—Filed